Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CTKB Stock Forecast 2026-2027
$4.51
Current Price
$596.64M
Market Cap
Buy 2
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to CTKB Price Targets
+66.3%
To High Target of $7.50
+16.4%
To Median Target of $5.25
+5.3%
To Low Target of $4.75
CTKB Price Momentum
-1.1%
1 Week Change
+13.9%
1 Month Change
+34.6%
1 Year Change
-10.7%
Year-to-Date Change
-27.0%
From 52W High of $6.18
+46.0%
From 52W Low of $3.09
📊 TOP ANALYST CALLS
Did CTKB Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Cytek Biosciences is one of their latest high-conviction picks.
Latest CTKB Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, CTKB has a neutral consensus with a median price target of $5.25 (ranging from $4.75 to $7.50). The overall analyst rating is Buy (7.5/10). Currently trading at $4.51, the median forecast implies a 16.4% upside. This outlook is supported by 2 Buy, 2 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Mason Carrico at Stephens & Co., suggesting a 5.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CTKB Analyst Ratings
2
Buy
2
Hold
0
Sell
CTKB Price Target Range
Low
$4.75
Average
$5.25
High
$7.50
Current: $4.51
Latest CTKB Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CTKB.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 13, 2026 | Stephens & Co. | Mason Carrico | Overweight | Maintains | $4.75 |
| May 12, 2026 | Morgan Stanley | Tejas Savant | Equal-Weight | Maintains | $5.50 |
| Jan 8, 2026 | TD Cowen | Buy | Maintains | $N/A | |
| Nov 11, 2025 | Piper Sandler | Overweight | Maintains | $N/A | |
| May 28, 2025 | Morgan Stanley | Equal-Weight | Maintains | $N/A | |
| May 12, 2025 | Goldman Sachs | Sell | Maintains | $N/A | |
| Mar 19, 2025 | Stephens & Co. | Overweight | Reiterates | $N/A | |
| Mar 4, 2025 | Piper Sandler | Overweight | Maintains | $N/A | |
| Nov 11, 2024 | Piper Sandler | Overweight | Maintains | $N/A | |
| Aug 13, 2024 | Piper Sandler | Overweight | Maintains | $N/A | |
| May 13, 2024 | Piper Sandler | Overweight | Maintains | $N/A | |
| Mar 6, 2024 | Piper Sandler | Overweight | Maintains | $N/A | |
| Feb 29, 2024 | Goldman Sachs | Buy | Maintains | $N/A | |
| Dec 14, 2023 | Stephens & Co. | Overweight | Initiates | $N/A | |
| Nov 9, 2023 | Morgan Stanley | Equal-Weight | Maintains | $N/A | |
| Oct 24, 2023 | Morgan Stanley | Equal-Weight | Maintains | $N/A | |
| Oct 16, 2023 | Piper Sandler | Overweight | Maintains | $N/A | |
| Jul 19, 2023 | Raymond James | Market Perform | Initiates | $N/A | |
| May 11, 2023 | Morgan Stanley | Equal-Weight | Maintains | $N/A | |
| May 10, 2023 | Goldman Sachs | Buy | Maintains | $N/A |
Cytek Biosciences, Inc. (CTKB) Competitors
The following stocks are similar to Cytek Biosciences based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Cytek Biosciences, Inc. (CTKB) Financial Data
Cytek Biosciences, Inc. has a market capitalization of $596.64M with a P/E ratio of 374.5x. The company generates $204.17M in trailing twelve-month revenue with a -36.2% profit margin.
Revenue growth is +6.5% quarter-over-quarter, while maintaining an operating margin of -41.8% and return on equity of -20.9%.
Valuation Metrics
Market Cap
$596.64M
Enterprise Value
$361.90M
P/E Ratio
374.5x
PEG Ratio
5.6x
Price/Sales
2.9x
Growth & Margins
Revenue Growth (YoY)
+6.5%
Gross Margin
+48.2%
Operating Margin
-41.8%
Net Margin
-36.2%
EPS Growth
+6.5%
Financial Health
Cash/Price Ratio
+45.0%
Current Ratio
4.7x
Debt/Equity
8.4x
ROE
-20.9%
ROA
-5.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Cytek Biosciences, Inc. (CTKB) Business Model
About Cytek Biosciences, Inc.
What They Do
Develops advanced flow cytometry technologies.
Business Model
The company generates revenue by designing and selling innovative flow cytometry systems and related products to life sciences researchers and clinicians. Its offerings enhance the accuracy and efficiency of cell analysis, providing significant value in research and clinical applications.
Additional Information
Cytek Biosciences Inc. operates in key areas such as immunology, oncology, and stem cell research, playing a vital role in drug discovery and personalized medicine. The company's advancements in cellular analysis technology are crucial for scientific discoveries and public health initiatives.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
676
CEO
Dr. Wenbin Jiang Ph.D.
Country
United States
IPO Year
2021
Website
cytekbio.comCytek Biosciences, Inc. (CTKB) Latest News & Analysis
Latest News
Cytek Biosciences to participate at the Singular Research's Las Vegas Invitational Conference
1 month ago
Quick Summary
Cytek Biosciences, Inc. (Nasdaq: CTKB) will participate in the Singular Research's Las Vegas Invitational Conference from June 14-16, 2026.
Why It Matters
Cytek Biosciences' participation in a significant conference may enhance visibility and attract investment interest, potentially impacting stock performance and market perception.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Cytek Biosciences to Unveil Next-Generation Spectral Flow Cytometry Innovations at CYTO 2026
1 month ago
Quick Summary
Cytek will debut its new 7-laser Borealis full spectrum flow cytometer at CYTO 2026, highlighting its advancements in cell analysis solutions.
Why It Matters
The launch of the new 7-laser Cytek Borealis could enhance Cytek's market position, potentially driving sales growth and impacting stock performance positively.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Cytek Biosciences, Inc. (CTKB) held its Q1 2026 earnings call, providing updates on financial performance and future outlook. Further details can be found in the full transcript.
Why It Matters
Cytek Biosciences' Q1 2026 earnings reveal financial performance, growth potential, and market positioning, crucial for assessing investment risks and opportunities.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Cytek Biosciences (Nasdaq: CTKB) reported its Q1 2026 financial results on May 7, 2026. Details on performance metrics were not included in the excerpt.
Why It Matters
Cytek Biosciences' Q1 financial results could influence stock performance, indicating company health and growth potential, impacting investment decisions in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Cytek Biosciences (CTKB) reported a quarterly loss of $0.12 per share, worse than the expected loss of $0.08, and compared to a loss of $0.09 per share a year prior.
Why It Matters
Cytek's larger-than-expected quarterly loss signals potential operational issues, which may lead to decreased investor confidence and impact stock performance.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Cytek Biosciences (Nasdaq: CTKB) will release its Q1 2026 financial results on May 7, 2026, after market close.
Why It Matters
Cytek Biosciences' upcoming financial report could impact stock performance, revealing insights into revenue growth, profitability, and market trends, influencing investor sentiment and decisions.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About CTKB Stock
What is Cytek Biosciences, Inc.'s (CTKB) stock forecast for 2027?
Based on our analysis of 3 Wall Street analysts, Cytek Biosciences, Inc. (CTKB) has a median price target of $5.25. The highest price target is $7.50 and the lowest is $4.75.
Is CTKB stock a good investment in 2027?
According to current analyst ratings, CTKB has 2 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.51. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CTKB stock?
Wall Street analysts predict CTKB stock could reach $5.25 in the next 12 months. This represents a 16.4% increase from the current price of $4.51. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Cytek Biosciences, Inc.'s business model?
The company generates revenue by designing and selling innovative flow cytometry systems and related products to life sciences researchers and clinicians. Its offerings enhance the accuracy and efficiency of cell analysis, providing significant value in research and clinical applications.
What is the highest forecasted price for CTKB Cytek Biosciences, Inc.?
The highest price target for CTKB is $7.50 from at , which represents a 66.3% increase from the current price of $4.51.
What is the lowest forecasted price for CTKB Cytek Biosciences, Inc.?
The lowest price target for CTKB is $4.75 from Mason Carrico at Stephens & Co., which represents a 5.3% increase from the current price of $4.51.
What is the overall CTKB consensus from analysts for Cytek Biosciences, Inc.?
The overall analyst consensus for CTKB is neutral. Out of 3 Wall Street analysts, 2 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $5.25.
How accurate are CTKB stock price projections?
Stock price projections, including those for Cytek Biosciences, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 14, 2026 2:28 AM UTC